Samsung Bio’s bet on Plant 4 continues to pay off with first-quarter earnings growth

Samsung Biologics’ Plant 4 remains a worthwhile $2 billion investment.

The CDMO said that the facility was key in its first-quarter gains and will continue to be for the rest of the year. Although the South Korean company did not break down its revenue by facility, it Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks